Synthesis and cytotoxic evaluation of some new phthalazinylpiperazine derivatives

Archiv der Pharmazie

Volumn 345, Issue 4, 2012, Pages 287-293

  Liu, Yajing ^a   Zhang, Shulan ^b   Li, Ye ^c   Wang, Jianqiang ^a   Song, Yu ^a   Gong, Ping ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b National Institutes Pharmceutical RandD Co Ltd   (China)

^c Northeast Pharmaceutical (Shenyang) Tech Development Co Ltd   (China)

Author keywords

Anti cancer; Phthalazinylpiperazine derivatives; Synthesis

Indexed keywords

1 (PIPERAZIN 1 YL )4 BENZYLPHTHALAZINE; 1 (PIPERAZIN 1 YL) 4 (PYRIDIN 4 YLMETHYL) PHTHALAZINE; 1 (PIPERAZIN 1 YL) 4 BENZYL 6,7 DIMETHOXYPHTHALAZINE; 1 CHLORO 4 BENZYL 6,7 DIMETHOXYPHTHALAZINE; 1 CHLORO 4 BENZYLPHTHALAZINE; 3 HYDROXY 2 (PYRIDIN 4 YL) 1H INDEN 1 ONE; 3 HYDROXY 2 PHENYL 1H INDEN 1 ONE; 3 HYDROXY 5,6 DIMETHOXY 2 PHENYL 1H INDEN 1 ONE; 4 (PYRIDIN 4 YLMETHYL)PHTHALAZIN 1(2H) ONE; 4 BENZYL 6,7 DIMETHOXYPHTHALAZIN 1(2H) ONE; 4 BENZYLPHTHALAZIN 1 OL; 5,6 DIMETHOXYISOBENZOFURAN 1(3H) ONE; ANTINEOPLASTIC AGENT; ETHYL 3,4 DIMETHOXYBENZOATE; ISOBENZOFURAN 1(3H) ONE; PHTHALAZINE DERIVATIVE; UNCLASSIFIED DRUG; VATALANIB; VERATRIC ACID;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CYTOTOXICITY; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; IN VITRO STUDY; INFRARED SPECTROSCOPY; LUNG CANCER; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; PHTHALAZINES; PIPERAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84859724187     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.201100250     Document Type: Article

References (12)

1. A. Matter, Drug Discov. Today, 2001, 6 (19), 1005-1024.
2. K. Miller-Moslin, S. Peukert, R. K. Jain, et al,., J. Med. Chem. 2009, 52 (13), 3954-3968.
3. S. Vasiliou, R. Castaner, J. Bolos, et al,., Drug Future, 2009, 34 (2), 101-105.
4. K. A. Menear, C. Adcock, F. C. Alonso, et al,., Bioorg. Med. Chem. Lett. 2008, 18 (14), 3942-3945.
5. K. A. Menear, C. Adcock, R. Boulter, et al,., J. Med. Chem. 2008, 51 (20), 6581-6591.
6. L. M. Jost, H. P. Gschwind, T. Jalava, et al,., Drug Metab. Dispos. 2006, 34 (11), 1817-1828.
7. A. J. D. Matthew, L. P. C. Eugene, K. R. Reeti, et al,., Bioorg. Med. Chem. 2009, 17 (2), 731-740.
8. J. A. Kaizerman, W. Aaron, S. An, et al,., Bioorg. Med. Chem. Lett. 2010, 20, 4607-4610.
9. P. De, M. Baltas, D. Lamoral-Theys, C. BruyÃre, et al,., Bioorg. Med. Chem. 2010, 18, 2537-2548.
10. G. Bold, K. H. Altmann, J. Frei, et al,., J. Med. Chem. 2000, 43 (12), 2310-2323.
11. M. Harig, B. Neumann, H. G. Stammler, et al,., Euro. J. Org. Chem. 2004, 11, 2381-2397.
12. S. Y. Xu, Method of Pharmacology, Public Health Publishing House, Beijing 2002, p 1784-1786.